Citigroup analyst Ronald Josey maintains Expedia Group (NASDAQ:EXPE) with a Neutral and lowers the price target from $118 to $102.
Cybin Acquires Exclusive License To Mindset Pharma’s Tryptamine Compounds Family
Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. (NYSE AMERICAN: CYBN) signed an agreement with next-gen psychedelics producer Mindset Pharma Inc.